Tag: MSD

Immutep starts a clinical trial collaboration with MSD

Immutep, a leading Australian biotechnology company, announced that it has entered into a clinical trial collaboration and supply agreement with MSD to evaluate the combination of Immutep’s lead immunotherapy product

Samsung Bioepis biosimilar cancer drug begun to sell in Europe

Korean biopharmaceutical firm Samsung Bioepis informed that its biosimilar cancer drug Ontruzant has begun selling in Britain following approval from a European regulator (EMA).

Eisai and MSD will jointly develop and commercialize a thyroid cancer therapy

Eisai Co., Ltd. and MSD agreed upon a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA (lenvatinib mesylate), an orally available tyrosine kinase inhibitor discovered by Eisai.

MSD and AKRIKHIN localized manufacturing of sitagliptin in Russia

MSD, an innovative global pharmaceutical company, and AKRIKHIN, a leading Russian pharmaceutical manufacturer, announced the successful localization of 100 mg finished dosage form of sitagliptin.

Ferring and MSD completed the Carbetocin Haemorrhage Prevention clinical trial

Ferring Pharmaceuticals and MSD announced the completion of CHAMPION (Carbetocin Haemorrhage Prevention), a global clinical trial conducted by the Human Reproduction Program at the World Health Organization.

MSD acquires an Australian biotechnology company

Merck and Viralytics Limited announced that the companies have signed a definitive agreement under which Merck will acquire Viralytics, an Australian company focused on oncolytic immunotherapy treatments for a range of cancers.

GlobalData expects that Merck will set to lead licensing deals in 2018

Companies’ financial success is often down to the strategic deals they are able to make with other pharmaceutical companies to enable them to develop the next leading drug in the market, observes GlobalData

MSD considers the possibility of localizing the vaccines manufacturing in Russia

According to Marwan Akar, MSD Director General in Russia, Kazakhstan and Belarus, the company is exploring the possibility of localizing in Russia the manufacturing of vaccines

N.A. Semashko National Research Institute and MSD announce their collaboration

N.A. Semashko National Research Institute of Public Health and MSD announced that they begin to collaborate

Pembrolizumab is included in Russian List of Vital and Essential Drugs for 2018

Pembrolizumab, an immuno-oncological medicine, is included in the approved List of Vital and Essential Drugs for 2018.

Merck will buy Rigontec to firm up its leadership in immuno-oncology

Merck, known as MSD, and Rigontec today announced that Merck will acquire Rigontec

AstraZeneca and Merck started oncology collaboration

AstraZeneca and Merck & Co., Inc., known as MSD outside of the United States and Canada, today announced that they have entered a global strategic oncology collaboration

MSD and R-Pharm invested 200 million rubles in the localization of Raltegravir

MSD, an international biopharmaceutical company, and R-Pharm, a leading Russian pharmaceutical company, have announced the successful completion of their joint project